Drug Profile
ZYDPLA 1
Alternative Names: ZYDPLA-1Latest Information Update: 11 Aug 2017
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 11 Aug 2017 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO) (Zydus Cadila pipeline, August 2017)
- 08 Oct 2015 ZYDPLA 1 is still in phase I trials for Type-2 diabetes mellitus in USA (Zydus pipeline, October 2015)
- 28 Feb 2014 Phase-I clinical trials in Type-2 diabetes mellitus in USA (Oral)